Building a Spanish-Latin American network on drug-induced liver injury: Much to get from a joint collaborative initiative

Annals of Hepatology

Volumn 11, Issue 4, 2012, Pages 544-549

  Bessone, Fernando ^a   Hernandez, Nelia ^b   Dávalos, Milagros ^c   Paraná, Raymundo ^d   Schinoni, Maria I ^d   Lizarzabal, Maribel ^e   Kershenobich, David ^f   Loaeza, Aurora ^f   Arrese, Marco ^g   Chirino, Ruby A ^h   Méndez Sanchez, Nahum ⁱ   Fay, Fabian ^j   Bruguera, Miguel ^k   Stephens, Camilla ^l   Lucena, Maria I ^l   Andrade, Raúl J ^l  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^c HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^d Hospital Universitario Profesor Edgard Santos   (Brazil)

^e HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

^f Hospital General de Méxicol   (Mexico)

^g PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^h HOSPITAL ÁNGELES DEL PEDREGAL   (Mexico)

ⁱ LIVER RESEARCH UNIT   (Mexico)

^j Centro de Diagnóstico Médico CIBIC   (Argentina)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; DICLOFENAC; ETORICOXIB; MINOCYCLINE; NITROFURANTOIN; TELITHROMYCIN; TROVAFLOXACIN;

ADAPTIVE IMMUNITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL COMPETENCE; CLINICAL DATA REPOSITORY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE REGISTRY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG SAFETY; ETHNIC DIFFERENCE; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HIGH RISK POPULATION; HISTOPATHOLOGY; HLA MATCHING; HUMAN; INTERNATIONAL RELATIONS; KNEE ARTHRITIS; LIVER TOXICITY; MORBIDITY; OSTEOARTHRITIS; POSTMARKETING SURVEILLANCE; SOUTH AND CENTRAL AMERICA; SPAIN; TOXIC HEPATITIS; COOPERATION; DRUG SURVEILLANCE PROGRAM; EDITORIAL; FACTUAL DATABASE; INCIDENCE; INTERNATIONAL COOPERATION; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PROGRAM DEVELOPMENT; REGISTER; SOUTH AMERICA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COOPERATIVE BEHAVIOR; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; HUMANS; INCIDENCE; INTERNATIONAL COOPERATION; ORGANIZATIONAL OBJECTIVES; PROGRAM DEVELOPMENT; REGISTRIES; SOUTH AMERICA; SPAIN;

EID: 84862016967     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31469-3     Document Type: Article

References (24)

1. Galan MV, Potts JA, Silverman, Gordon GC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005; 39: 64-7.
2. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachko ria K, García-Ruiz E, García-Muñoz B, et al. Drug-induced liver injury: an analysis of 46 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
3. Aithal PG, Day CP. The natural history of histologically proved drug-induced liver disease. Gut 1999; 44: 731-5.
4. Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, Fattinger K. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61: 135-43.
5. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBaseTM: unified list based on international collaborative work. Drug Saf 2010; 33: 503-22.
6. Bessone F, Colombato L, Fassio E, Reggiardo MV, Vorobioff J, Tanno H. The spectrum of nimesulide-induced-hepatotoxicity. An overview. Anti-Inflamm & Anti-Allergy Agents Med Chem 2010; 9: 355-65.
7. Bessone F, Tanno H. Hepatotoxicidad inducida por antiinflamatorios no esteroides. Gastroenterol Hepatol 2000; 23: 200-5.
8. Bessone F. Non Steroideal Anti-inflammatory Drugs (NSAIDs): What is the actual risk of liver damage? World J Gastroenterol 2010; 16(45): 5651-61.
9. Walker SL, Kennedy F, Niamh N, McCormick A. Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol and Drug Saf 2008; 17: 1108-12.
10. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al. Case definition and phenotype standardization in drug-induced liver injury (DILI). Clin Pharmacol Ther 2011; 55: 683-91.
11. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999; 319: 1541.
12. Banks AT, Zmmerman HJ, Ihak KG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820-7.
13. Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How Common Is Diclofenac-Associated Liver Injury? Analysis of 17.289 Arthritis Patients in a Long-Term Prospective Clinical Trial. Am J Gastroenterol 2009; 104: 356-62.
14. Lucena MI, Cohen H, Hernández N, Bessone F, Dacoll C, Stephens C, Borraz Y, et al. Hepatotoxicidad, un problema global con especificidades locales: hacia la creación de una Red Hispano Latinoamericana de Hepatotoxicidad. Gastroenterol Hepatol 2011; 34(5): 361-8.
15. Drug-induced Liver Injury Network (DILIN). Available from: http://dilin.dcri.duke.edu/web
16. Asociación Latinoamericana de Hepatología (ALEH). Available from: http://www.kenes.com/alehigado_/ historia.htm
17. International Serious Adverse Events Consortium (iSAEC). Available from: http://www.saeconsortium.org/
18. Burroughs V, Maxey R, Levy R. Racial and ethnic differen ces in response to medicines: towards individualized phar maceutical treatment. J Natl Med Assoc 2002; 94(10 Suppl.): 1-26.
19. Daly A, Day C. Genetic Association Studies in Drug-induced Liver Injury. Semin Liver Dis 2009; 29: 400-11.
20. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day C., et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav induced liver injury. J Hepatol 2010; 53: 1049-53.
21. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxaci Ilin. Nat Genet 2009; 41: 816-9.
22. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day C., et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple hla class I and II alleles. Gastroenterology 2011; 141: 338-47.
23. Stephens C, Lopez-Nevot MI, Lucena MI, Ruiz-Cabello F, Ulzurrun E, Cabello MC, Lucena MI, et al. The HLA class I B*1801 allele influences hepatocellular expression of amoxicillin clavulanate liver damage and outcome in Spanish patients. J Hepatol 2010; 52: S439.
24. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced Liver Injury: Insights from genetic studies. Pharmacogenomics 2009; 10: 1467 87.